BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The Company offers human and plant stem cell derived cosmetic and skin care products. Its programs relate to the treatment of disc/spine disease and metabolic disorders and include Disc/Spine Program (brtxDISC) and Metabolic Program (ThermoStem). Its curved needle device (CND) is a needle system with a curved inner cannula to allow access to difficult-to-locate regions for the delivery or removal of fluids and other substances. The CND is intended to deliver stem cells and/or other therapeutic products or material to the interior of a human intervertebral disc, the spine region, or other areas of the body. The device relies on the use of pre-curved nested cannulae that allows the cells or material to be deposited in the posterior and lateral aspects of the disc to which direct access is not possible due to outlying structures.
Industry, Sector and Symbol:
- 50 Day Moving Avg: $3.34
- 200 Day Moving Avg: $3.65
- 52 Week Range: $2.70 - $5.01
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: $38,075.00
- Price / Sales: N/A
- Book Value: ($1.04) per share
- Price / Book: -2.98
- EBIDTA: ($8,380,000.00)
- Net Margins: -13,735.90%
- Return on Assets: -758.82%
- Average Volume: 1,178 shs.
Frequently Asked Questions for BioRestorative Therapies (NASDAQ:BRTX)
What is BioRestorative Therapies' stock symbol?
BioRestorative Therapies trades on the NASDAQ under the ticker symbol "BRTX."
Who are some of BioRestorative Therapies' key competitors?
Some companies that are related to BioRestorative Therapies include AEterna Zentaris (AEZS), BioSig Technologies (BSGM), Imprimis Pharmaceuticals (IMMY), CafePress (PRSS), Good Times Restaurants (GTIM), Orion Energy Systems (OESX), Ekso Bionics Holdings (EKSO), Sunworks (SUNW), Cemtrex (CETX), Jason Industries (JASN), Auxilio (AUXO), ContraVir Pharmaceuticals (CTRV), Orexigen Therapeutics (OREX), Pernix Therapeutics Holdings (PTX), Medley Management (MDLY), Energy Focus (EFOI), Senomyx (SNMX) and Interpace Diagnostics Group (IDXG).
Who are BioRestorative Therapies' key executives?
BioRestorative Therapies' management team includes the folowing people:
- Mark Weinreb, Chairman of the Board, President, Chief Executive Officer
- Robert B. Catell, Independent Director
- John M. Desmarais, Independent Director
- A. Jeffrey Radov, Independent Director
- Paul Jude Tonna, Independent Director
How do I buy BioRestorative Therapies stock?
Shares of BioRestorative Therapies can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioRestorative Therapies' stock price today?
MarketBeat Community Rating for BioRestorative Therapies (NASDAQ BRTX)MarketBeat's community ratings are surveys of what our community members think about BioRestorative Therapies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of BioRestorative Therapies stock can currently be purchased for approximately $3.10.
Consensus Ratings for BioRestorative Therapies (NASDAQ:BRTX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for BioRestorative Therapies (NASDAQ:BRTX)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for BioRestorative Therapies (NASDAQ:BRTX)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for BioRestorative Therapies (NASDAQ:BRTX)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for BioRestorative Therapies (NASDAQ:BRTX)
No dividend announcements for this company have been tracked by MarketBeat.com
Headline Trends for BioRestorative Therapies (NASDAQ:BRTX)
Latest Headlines for BioRestorative Therapies (NASDAQ:BRTX)
|BioRestorative Therapies, Inc. :BRTX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017|
finance.yahoo.com - August 16 at 5:16 PM
|BioRestorative Therapies to Present at 6th Annual Marcum MicroCap Conference|
finance.yahoo.com - June 14 at 4:43 PM
|BioRestorative Therapies, Inc. :BRTX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017|
finance.yahoo.com - May 24 at 12:57 PM
|BIORESTORATIVE THERAPIES, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Change in Directors or Pri|
biz.yahoo.com - February 14 at 9:42 PM
|BIORESTORATIVE THERAPIES, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities|
biz.yahoo.com - February 8 at 4:16 PM
|BioRestorative Therapies Receives FDA Clearance to Initiate Phase 2 Clinical Trial for the Treatment of Patients with Degenerative Disc Disease|
finance.yahoo.com - February 8 at 4:16 PM
|9:46 am BioRestorative Therapies submits an Investigational New Drug Application to the FDA to seek clearance to commence a clinical trial using its lead cell therapy candidate, BRTX-100, to treat chronic lower back pain due to degenerative|
us.rd.yahoo.com - January 9 at 10:09 PM
|BIORESTORATIVE THERAPIES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders|
biz.yahoo.com - October 20 at 8:51 PM
|No Adverse Events and Overall Improvement Reported by Study Patients|
globenewswire.com - September 13 at 8:49 AM
|BioRestorative Therapies Announces Publication in Medical Journal of Positive Results of Long-Term Safety and Feasibility Study Using Cell Therapy to Treat Patients with Degenerative Disc Disease|
finance.yahoo.com - September 12 at 3:51 PM
|9:46 am BioRestorative Therapies announces publication in Medical Journal of results of long-term safety and feasibility study using cell therapy to treat patients with degenerative disc disease|
finance.yahoo.com - September 12 at 3:51 PM
|BioRestorative Therapies Announces Presentation at 3rd Annual Regenerative Medicine Essentials Course|
finance.yahoo.com - July 13 at 10:47 AM
|BIORESTORATIVE THERAPIES, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under a|
biz.yahoo.com - June 30 at 4:36 PM
|BioRestorative Therapies Announces Completion of Human Safety and Feasibility Study on the Use of Hypoxic Cultured Stem Cells to Treat Chronic Lower Back Pain|
finance.yahoo.com - June 28 at 9:45 AM
|BIORESTORATIVE THERAPIES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits|
biz.yahoo.com - June 2 at 6:02 AM
|BioRestorative Therapies to Present at 5th Annual Marcum MicroCap Conference|
finance.yahoo.com - May 31 at 9:45 AM
|BioRestorative Therapies Announces Promising Data to Advance its Program for the Treatment of Metabolic Disorders|
finance.yahoo.com - May 23 at 9:45 AM
|BIORESTORATIVE THERAPIES, INC. Files SEC form 10-Q, Quarterly Report|
biz.yahoo.com - May 13 at 5:39 PM
|BIORESTORATIVE THERAPIES, INC. Files SEC form 10-K, Annual Report|
biz.yahoo.com - March 30 at 5:35 PM
|BIORESTORATIVE THERAPIES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of E|
biz.yahoo.com - March 24 at 11:55 AM
|BIORESTORATIVE THERAPIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial|
biz.yahoo.com - February 24 at 1:53 PM
|BIORESTORATIVE THERAPIES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Change in Dir|
biz.yahoo.com - December 28 at 11:22 AM
|BioRestorative Therapies Provides Company Updates With Shareholder Letter|
finance.yahoo.com - December 21 at 8:00 AM
|BIORESTORATIVE THERAPIES, INC. Financials|
finance.yahoo.com - December 8 at 1:18 PM
|BioRestorative Therapies, Inc. Announces Opening of New Headquarters and Laboratory Facility in New York|
finance.yahoo.com - April 14 at 7:45 AM
|BioRestorative Therapies Appoints Charles S. Ryan, J.D., Ph.D. to its Board of Directors|
finance.yahoo.com - April 8 at 8:52 AM
BioRestorative Therapies (BRTX) Chart for Sunday, September, 24, 2017